N/A N=10 Improving Walking in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
N/A N=35 Exercise Rehabilitation in Veterans With PAD
Peripheral Arterial Disease · Intermittent Claudication
Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale
N/A N=347 Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters
N/A N=20 Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in the Mean Daily Walking Distance Over 7 Consecutive Days — 754.2; -1160 steps
N/A N=238 Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease
Peripheral Artery Disease · Amputation · Smoking
Primary: Positive Predictive Value of Digital ABI in Diagnosing PAD — 8; 2 Participants
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
N/A N=67 Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
Peripheral Arterial Disease
Primary: Absolute Claudication Distance (ACD) — 54.374; 0.792 Meters
N/A N=33 Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
N/A N=28 Ankle-foot Orthoses for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units
N/A N=14 Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Endothelial Function — 6.13; 3.78 % dilation
N/A N=12 Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease
Primary: Mean Acute Flow Rate Difference During TUS Treatment Sessions — 27.3 Percent change (%)
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
N/A N=797 Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)
Peripheral Arterial Disease · Quality of Life · Quality of Care
Primary: Peripheral Artery Disease (PAD) - Specific Health Status — 70.7; 66.9 units on a scale of 0-100
N/A N=56 Pain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID)
Peripheral Arterial Disease · Intermittent Claudication
Primary: Change in Absolute Claudication Distance (ACD) in Meters From Baseline — -16.8; -6.7; 76.2; -0.9 metres
N/A N=1,204 Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes
Peripheral Arterial Occlusive Disease
Primary: Procedural Success of Endovascular PAD Treatment(s) — 83.6; 75.8; 68.5 percent of procedures
N/A N=16 Heat Therapy to Reduce Pain and Improve Walking Tolerance
Peripheral Arterial Disease
Primary: Peak Walking Time — 955.6; 947.7 seconds
Phase 2 N=46 Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Peripheral Artery Disease (PAD); Intermittent Claudication
Primary: Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths — 18; 17; 4; 4 Participants
Phase 1 N=6 A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
Peripheral Arterial Disease · Intermittent Claudication
Primary: Change in Six-minute Walk Distance — 32.3 Meters
N/A N=147 Impacts of Aquatic vs Land Walking on Vascular Health and Exercise Tolerance in Patients With Peripheral Artery Disease
Peripheral Artery Disease · Vascular Function · Exercise Tolerance
Primary: Peripheral Arterial Stiffness — 12.3; 10.2; 12.4; 12.8 meters per second
N/A N=18 Exercise and Weight Loss in PAD
Peripheral Arterial Disease
Primary: Difference in Time to Onset of Calf Pain (Claudication Onset Time) Pre-intervention to Post-intervention — 396; 140 seconds — p=0.028
Phase 2 N=119 Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease (PAD)
Primary: Segment-level Sensitivity and Specificity of VE-MRI at 3 Ferumoxytol Dosing Levels and Differences in Sensitivity and Specificity by Dose Group — 71.8; 76.8; 81.8; 71.2…
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
N/A N=21 Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in Vasodilator Capacity — 16.2; 16.4; 16.5; 14.2 ml/100ml tissue/min
Phase 2 N=39 Hepatocyte Growth Factor to Improve Functioning in PAD
Peripheral Artery Disease
Primary: Six-minute Walk Distance — 17.01; 3.46 meters — p=0.7586
N/A N=85 Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Peripheral Artery Disease
Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32
Phase 2 N=159 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions